The preset invention relates to use of antipsychotic phenothiazine derivative for eliminating cancer stem cells (CSCs) and/or preventing a cancer. The invention also provides a pharmaceutical composition for treating a cancer, and/or preventing or delaying cancer recurrence comprising trifluoperazine and an anti-cancer drug, such as gefitinib or cisplatin.

The present invention relates to use of antipsychotic phenothiazine derivative for eliminating cancer stem cells (CSCs) and/or preventing a cancer. The invention also provides a pharmaceutical composition for treating a cancer, and /or preventing or delaying cancer recurrence comprising trifluoperazine and an anti-cancer drug, such as gefitinib or cisplatin.

Disclosed is the use of a dopamine receptor D2 inhibitor medicament for treating depression improving cognition and/or treating other syndromes conditions or diseases for which anti-depressant agents are prescribed. The dopamine receptor D2 inhibitor medicament is formulated for administration in an administration cycle the administration cycle comprising: i. administering the D2 receptor inhibitor to elevate amounts of the D2 receptor's high affinity state inducing dopamine receptor supersensit...

A method for treating coronavirus infection by administering to a subject in need of the treatment an effective amount of one or more of the following compounds: aklavin sanguinarine amiodarone chlorpromazine clomiphene dihydroergotamine dipyridamole emetine ephedrine prochlorperazine promazine propiomazine aminacrine fluphenazine fenoterol peruvoside proglumide atenolol nerifolin nefopam cycloheximide avermectin B1 bepridil cinnarizine ethisterone pararosaniline methylbenzethonium niclosamide p...

Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor e.g. a morphinan such as dextromethorphan or dextrorphan or that block a major intracellular consequence of NMDA-receptor activation e.g. a ganglioside such as GM1 or GT1b a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide inhibit the development of tolerance to and/or dependence on addictive drugs e.g. narcotic analgesics such as morphine codeine et...

Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor e.g. a morphinan such as dextromethorphan or dextrorphan or 'that block a major intracellular consequence of NMDA receptor activation e.g. a ganglioside such as GM1 or GT1b a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide inhibit the development of tolerance to and/or dependence on addictive drugs e.g. narcotic analgesics such as morphine codeine e...